Who is eligible for clinical trial NCT03128866?

Participants must meet the protocol's inclusion criteria for Pelvic Mass. Confirm all requirements with the study coordinator.

Does clinical trial NCT03128866 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-03

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery (NCT03128866)

Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)

🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: M.D. Anderson Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (11 items).

Location: M D Anderson Cancer Center — Houston, Texas

🧪 Interventions in This Study

Tranexamic Acid (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Both pediatric and adult patients can be eligible to participate
Cognitively impaired and non-English speakers can be eligible to participate.
Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patient with a history of genetic prothrombotic state
Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis
Patients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstruction
Female patients will not be eligible for this study if she is either pregnant or nursing at the time of enrollment
Patients will not be eligible if they have a history of color vision defects
Patients will not be eligible if they have a history of retinal vein or artery occlusion
Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
Patients will not be eligible if they present with moderate to severe decrease in creatinine clearance (estimated glomerular filtration rate \[eGFR\] \< 45 mL/min/1.73m2)
Patients will not be eligible if they present or have a history of seizure disorder

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Pelvic Mass clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗